Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules

George T. Mercier, Pramod N. Nehete, Marco F. Passeri, Bharti N. Nehete, Eric A. Weaver, Nancy Smyth Templeton, Kimberly Schluns, Stephanie S. Buchl, K. Jagannadha Sastry, Michael A. Barry

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Targeted delivery of vaccine candidates to the gastrointestinal (GI) tract holds potential for mucosal immunization, particularly against mucosal pathogens like the human immunodeficiency virus (HIV). Among the different strategies for achieving targeted release in the GI tract, namely the small intestine, pH sensitive enteric coating polymers have been shown to protect solid oral dosage forms from the harsh digestive environment of the stomach and dissolve relatively rapidly in the small intestine by taking advantage of the luminal pH gradient. We developed an enteric polymethacrylate formulation for coating hydroxy-propyl-methyl-cellulose (HPMC) capsules containing lyophilized Adenoviral type 5 (Ad5) vectors expressing HIV-1 gag and a string of six highly-conserved HIV-1 envelope peptides representing broadly cross-reactive CD4+ and CD8+ T cell epitopes. Oral immunization of rhesus macaques with these capsules primed antigen-specific mucosal and systemic immune responses and subsequent intranasal delivery of the envelope peptide cocktail using a mutant cholera toxin adjuvant boosted cellular immune responses including, antigen-specific intracellular IFN-γ-producing CD4+ and CD8+ effector memory T cells in the intestine. These results suggest that the combination of oral adenoviral vector priming followed by intranasal protein/peptide boosting may be an effective mucosal HIV vaccination strategy for targeting viral antigens to the GI tract and priming systemic and mucosal immunity.

Original languageEnglish (US)
Pages (from-to)8687-8701
Number of pages15
JournalVaccine
Volume25
Issue number52
DOIs
StatePublished - Dec 17 2007

Fingerprint

oral vaccination
Human immunodeficiency virus
Macaca mulatta
gastrointestinal system
Capsules
Gastrointestinal Tract
Immunization
Mucosal Immunity
Vaccines
HIV
peptides
vaccines
Human immunodeficiency virus 1
Peptides
coatings
Small Intestine
small intestine
HIV-1
mouth
T-lymphocytes

Keywords

  • Adenoviral vectors
  • Enteric coatings
  • HIV-1 peptides
  • Mucosal vaccination
  • Oral delivery

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Mercier, G. T., Nehete, P. N., Passeri, M. F., Nehete, B. N., Weaver, E. A., Templeton, N. S., ... Barry, M. A. (2007). Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. Vaccine, 25(52), 8687-8701. https://doi.org/10.1016/j.vaccine.2007.10.030

Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. / Mercier, George T.; Nehete, Pramod N.; Passeri, Marco F.; Nehete, Bharti N.; Weaver, Eric A.; Templeton, Nancy Smyth; Schluns, Kimberly; Buchl, Stephanie S.; Sastry, K. Jagannadha; Barry, Michael A.

In: Vaccine, Vol. 25, No. 52, 17.12.2007, p. 8687-8701.

Research output: Contribution to journalArticle

Mercier, GT, Nehete, PN, Passeri, MF, Nehete, BN, Weaver, EA, Templeton, NS, Schluns, K, Buchl, SS, Sastry, KJ & Barry, MA 2007, 'Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules', Vaccine, vol. 25, no. 52, pp. 8687-8701. https://doi.org/10.1016/j.vaccine.2007.10.030
Mercier, George T. ; Nehete, Pramod N. ; Passeri, Marco F. ; Nehete, Bharti N. ; Weaver, Eric A. ; Templeton, Nancy Smyth ; Schluns, Kimberly ; Buchl, Stephanie S. ; Sastry, K. Jagannadha ; Barry, Michael A. / Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. In: Vaccine. 2007 ; Vol. 25, No. 52. pp. 8687-8701.
@article{dd93d69e55ab4853a261bbac1f6a9d2e,
title = "Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules",
abstract = "Targeted delivery of vaccine candidates to the gastrointestinal (GI) tract holds potential for mucosal immunization, particularly against mucosal pathogens like the human immunodeficiency virus (HIV). Among the different strategies for achieving targeted release in the GI tract, namely the small intestine, pH sensitive enteric coating polymers have been shown to protect solid oral dosage forms from the harsh digestive environment of the stomach and dissolve relatively rapidly in the small intestine by taking advantage of the luminal pH gradient. We developed an enteric polymethacrylate formulation for coating hydroxy-propyl-methyl-cellulose (HPMC) capsules containing lyophilized Adenoviral type 5 (Ad5) vectors expressing HIV-1 gag and a string of six highly-conserved HIV-1 envelope peptides representing broadly cross-reactive CD4+ and CD8+ T cell epitopes. Oral immunization of rhesus macaques with these capsules primed antigen-specific mucosal and systemic immune responses and subsequent intranasal delivery of the envelope peptide cocktail using a mutant cholera toxin adjuvant boosted cellular immune responses including, antigen-specific intracellular IFN-γ-producing CD4+ and CD8+ effector memory T cells in the intestine. These results suggest that the combination of oral adenoviral vector priming followed by intranasal protein/peptide boosting may be an effective mucosal HIV vaccination strategy for targeting viral antigens to the GI tract and priming systemic and mucosal immunity.",
keywords = "Adenoviral vectors, Enteric coatings, HIV-1 peptides, Mucosal vaccination, Oral delivery",
author = "Mercier, {George T.} and Nehete, {Pramod N.} and Passeri, {Marco F.} and Nehete, {Bharti N.} and Weaver, {Eric A.} and Templeton, {Nancy Smyth} and Kimberly Schluns and Buchl, {Stephanie S.} and Sastry, {K. Jagannadha} and Barry, {Michael A.}",
year = "2007",
month = "12",
day = "17",
doi = "10.1016/j.vaccine.2007.10.030",
language = "English (US)",
volume = "25",
pages = "8687--8701",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "52",

}

TY - JOUR

T1 - Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules

AU - Mercier, George T.

AU - Nehete, Pramod N.

AU - Passeri, Marco F.

AU - Nehete, Bharti N.

AU - Weaver, Eric A.

AU - Templeton, Nancy Smyth

AU - Schluns, Kimberly

AU - Buchl, Stephanie S.

AU - Sastry, K. Jagannadha

AU - Barry, Michael A.

PY - 2007/12/17

Y1 - 2007/12/17

N2 - Targeted delivery of vaccine candidates to the gastrointestinal (GI) tract holds potential for mucosal immunization, particularly against mucosal pathogens like the human immunodeficiency virus (HIV). Among the different strategies for achieving targeted release in the GI tract, namely the small intestine, pH sensitive enteric coating polymers have been shown to protect solid oral dosage forms from the harsh digestive environment of the stomach and dissolve relatively rapidly in the small intestine by taking advantage of the luminal pH gradient. We developed an enteric polymethacrylate formulation for coating hydroxy-propyl-methyl-cellulose (HPMC) capsules containing lyophilized Adenoviral type 5 (Ad5) vectors expressing HIV-1 gag and a string of six highly-conserved HIV-1 envelope peptides representing broadly cross-reactive CD4+ and CD8+ T cell epitopes. Oral immunization of rhesus macaques with these capsules primed antigen-specific mucosal and systemic immune responses and subsequent intranasal delivery of the envelope peptide cocktail using a mutant cholera toxin adjuvant boosted cellular immune responses including, antigen-specific intracellular IFN-γ-producing CD4+ and CD8+ effector memory T cells in the intestine. These results suggest that the combination of oral adenoviral vector priming followed by intranasal protein/peptide boosting may be an effective mucosal HIV vaccination strategy for targeting viral antigens to the GI tract and priming systemic and mucosal immunity.

AB - Targeted delivery of vaccine candidates to the gastrointestinal (GI) tract holds potential for mucosal immunization, particularly against mucosal pathogens like the human immunodeficiency virus (HIV). Among the different strategies for achieving targeted release in the GI tract, namely the small intestine, pH sensitive enteric coating polymers have been shown to protect solid oral dosage forms from the harsh digestive environment of the stomach and dissolve relatively rapidly in the small intestine by taking advantage of the luminal pH gradient. We developed an enteric polymethacrylate formulation for coating hydroxy-propyl-methyl-cellulose (HPMC) capsules containing lyophilized Adenoviral type 5 (Ad5) vectors expressing HIV-1 gag and a string of six highly-conserved HIV-1 envelope peptides representing broadly cross-reactive CD4+ and CD8+ T cell epitopes. Oral immunization of rhesus macaques with these capsules primed antigen-specific mucosal and systemic immune responses and subsequent intranasal delivery of the envelope peptide cocktail using a mutant cholera toxin adjuvant boosted cellular immune responses including, antigen-specific intracellular IFN-γ-producing CD4+ and CD8+ effector memory T cells in the intestine. These results suggest that the combination of oral adenoviral vector priming followed by intranasal protein/peptide boosting may be an effective mucosal HIV vaccination strategy for targeting viral antigens to the GI tract and priming systemic and mucosal immunity.

KW - Adenoviral vectors

KW - Enteric coatings

KW - HIV-1 peptides

KW - Mucosal vaccination

KW - Oral delivery

UR - http://www.scopus.com/inward/record.url?scp=36549056067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36549056067&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2007.10.030

DO - 10.1016/j.vaccine.2007.10.030

M3 - Article

C2 - 18063450

AN - SCOPUS:36549056067

VL - 25

SP - 8687

EP - 8701

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 52

ER -